Introduction
============

The routine treatment of active tuberculosis and latent tuberculosis infection (LTBI) has increased with the availability of biological drugs. The side effects of anti-tuberculosis drugs include various hematologic side effects. Reports indicate that isoniazid (INH) causes eosinophilia, leukocytosis, neutropenia, thrombocytopenia, autoimmune hemolytic anemia, pure red cell aplasia (PRCA), and sideroblastic anemia. PRCA is a rare complication caused by the disruption of hematopoiesis by INH. Secondary PRCA can be induced by viral infections, anti-erythropoietin antibodies, thymoma, chronic lymphocytic leukemia, pregnancy, drugs, and autoimmune disorders such as rheumatoid arthritis (RA), myasthenia gravis (MG), mixed connective tissue disease (MCTD), and systemic lupus erythematosus (SLE) ([@B1]).

PRCA is characterized by erythroblastopenia, with otherwise normal bone marrow production. Severe PRCA is associated with a marked decrease in the number of reticulocytes and the absence of erythroblasts in bone marrow. Drugs such as procainamide, sulfa, diphenylhydantoin, amide drugs, ticlopidine, allopurinol, penicillamine, azathioprine, and ribavirin can induce PRCA ([@B1]), but \<5% of all cases of PRCA are drug-induced. INH is also reported to induce secondary PRCA, and there have been two studies describing Asian patients with INH-induced PRCA ([@B2],[@B3]). Furthermore, cases of autoimmune disorders exacerbated by INH-induced PRCA are very rare; this is the first case report of a patient with sarcoidosis. The observations should be considered by clinicians managing patients on anti-tuberculosis treatment.

Case Report
===========

A 41-year-old woman, who had been followed-up for non-B, non-C, non-alcoholic chronic hepatitis, presented with increased exertional dyspnea and thus was hospitalized. The diagnosis was worsening interstitial pneumonia by sarcoidosis, and she was started on prednisolone (PSL) 20 mg/day. Sarcoidosis had been diagnosed two years prior, when she had presented with pulmonary manifestations of sarcoidosis. At that time, she had had elevated angiotensin-converting enzyme and γ-globulin levels and a negative tuberculin skin test result. During the current admission, an interferon-gamma release assay (IGRA) revealed positive results. Sputum cultures were negative for *Mycobacterium tuberculosis*, and there was no evidence of active pulmonary tuberculosis on computed tomography (CT). We diagnosed the patient with LTBI. To prevent inducing an active case of tuberculosis due to the use of oral corticosteroid therapy, INH treatment for LTBI was started one week after the initiation of PSL.

Approximately three months later at a routine follow-up visit, the patient reported the recurrence of exertional dyspnea starting several weeks prior. A laboratory analysis showed a hemoglobin level of 5.9 g/dL, a reticulocyte count of 2,000 /μL (0.1%), and unchanged thrombocytopenia secondary to splenomegaly and chronic liver dysfunction ([Table 1](#t001){ref-type="table"}). Iron, vitamin B12, and folic acid levels were normal. CT, esophagogastroduodenoscopy, and colonoscopy showed no evidence of worsening interstitial pneumonia or internal bleeding. A bone marrow evaluation confirmed a significant decrease in the number of erythroblasts, with a high myeloid:erythroid ratio (206:1), but no cell dysplasia ([Figure A and B](#g001){ref-type="fig"}). There was no evidence suggesting any other collagen disease, malignant tumor, or infections such as infectious mononucleosis or erythema infectiosum. The patient had no fever, exanthema, or arthralgia, and none of her family members had infections such as infectious mononucleosis or erythema infectiosum. Furthermore, viral infections caused by parvovirus, mumps, and Epstein Barr virus were excluded by viral DNA and antibody tests. We therefore presumed that the PRCA was induced by INH, not by a viral infection. The administration of INH 250 mg/day for 10 weeks was thus terminated, and the patient received a red blood cell transfusion. Two weeks later, the reticulocyte count had increased, and the anemia had improved. The dose of PSL was decreased, and no other medication changes were made. We diagnosed this patient with INH-induced PRCA complicated by sarcoidosis. More than one year, the patient has remained well, with stable sarcoidosis and no recurrence of PRCA.

###### 

Laboratory Data.

  ----------------------- -------------- --------- ----------------------- ------- --------
  Blood cell count        Biochemistry                                             
  White blood cells       4,200          /μL       Total bilirubin         1.5     mg/dL
  Neutrophils             81.1           \%        AST                     35      IU/L
  Lymphocytes             13.9           \%        ALT                     29      IU/L
  Eosinophils             1.2            \%        LDH                     283     IU/L
  Basophils               0              \%        ALP                     131     IU/L
  Monocytes               3.8            \%        γ-GTP                   27      IU/L
  Red blood cells         166×10^4^      /μL       Total protein           6       g/dL
  Hemoglobin              5.9            g/dL      Albumin                 3.1     g/dL
  Hematocrit              16.9           \%        Blood urea nitrogen     13      mg/dL
  MCV                     101.8          fL        Creatinine              0.49    mg/dL
  MCH                     35.5           pg        Sodium                  137     mEq/L
  MCHC                    34.9           \%        Potassium               4       mEq/L
  Platelets               5.4×10^4^      /μL       Chloride                104     mEq/L
  Reticulocyte count      2,000          /μL       Calcium                 8.1     mg/dL
                                                   Serum iron              240     μg/dL
  Infection                                        UIBC                    13      μg/dL
  Parvovirus B19 PCR      \<100          copy/mL   Ferritin                557.1   ng/mL
  EBV                                              Vitamin B12             408     pg/mL
  EA IgG                  (+)                      Folic acid              6       ng/mL
  EBNA IgG                (+)                                                      
  VCA IgG                 (+)                      Serology                        
  VCA IgM                 (-)                      CRP                     0.3     mg/dL
  Mumps                                            Rheumatoid factor       \<10    IU/mL
  IgM                     (-)                      Anti-nuclear antibody   20      Index
  Neutralizing antibody   (+)                                                      
                                                   Coagulation                     
                                                   APTT                    31      second
                                                   PT-INR                  1.07    
  ----------------------- -------------- --------- ----------------------- ------- --------

MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, CRP: C-reactive protein, PCR: polymerase chain reaction, EBV: Epstein-Barr virus, EA: early antigen, EBNA: EBV nuclear antigen, VCA: virus capsid antigen, AST: aspartate transaminase, ALT: alanine transaminase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transferase, UIBC: unsaturated iron binding capacity, APTT: activated partial thromboplastin time, PT-INR: prothrombin time-international normalized ratio

![Bone marrow histology of a patient with isoniazid-induced pure red cell aplasia. The bone marrow showed marked erythroid hypoplasia with a decreased number of erythroblasts. Bar=20 μm.](1349-7235-56-2753-g001){#g001}

Discussion
==========

INH-induced PRCA is a very rare form of drug-induced PRCA, with only 16 cases reported since 1964 ([Table 2](#t002){ref-type="table"}). This is the first case report of a patient with sarcoidosis in the English language literature. Two cases occurring in Asian patients were reported by Nakamura et al. in 2010 ([@B2]) and Shukla et al. in 2014 ([@B3]). No influence of race or ethnicity on the onset of PRCA was found. In the present case, an oral corticosteroid was initiated for the treatment of worsening sarcoidosis, with the concomitant use of INH for LTBI. Secondary PRCA associated with autoimmune disorders such as RA, MG, MCTD, and SLE has been reported ([@B4]). However, very little has been reported about sarcoidosis and PRCA. Hematopoietic complications are very rare in sarcoidosis. We found two articles describing PRCA in association with sarcoidosis. In one, the patient was diagnosed with parvovirus B19-induced red blood cell aplasia and thrombocytopenia ([@B5]). In the other, sarcoidosis was complicated by red blood cell aplasia and malakoplakia ([@B6]). Evidence of a direct association between PRCA and sarcoidosis was not found in these cases, nor was it noted in the present case. INH has been shown to induce PRCA. The patient in the present case showed improvement after the discontinuation of INH. Notably, in our case, PSL was started one week prior to starting INH, suggesting that pretreatment with PSL might not have a protective effect against the development of INH-induced PRCA.

###### 

Case Reports of Isoniazid-induced Pure Red Cell Aplasia.

  Case No.   Reference No.   Age   Sex   Duration of exposure (months)   Days Recovery (Days)   Cooms test   Dosage of isoniazid (mg)   Other drugs         Transfusion   Hb (g/dL)   Reticulocyte (%)   Complications
  ---------- --------------- ----- ----- ------------------------------- ---------------------- ------------ -------------------------- ------------------- ------------- ----------- ------------------ -------------------------
  1          8               32    M     6                               6                      (+)          750                        PAS, Pyr, Insulin   (+)           4.1         0.1                Type1 diabetes mellitus
  2          11              42    M     4.5                             11                     (-)          300                        EB, Pyr, PB         (+)           5.5         0.2                Mental retardation
  3          11              66    F     4                               35                     NR           NR                         Pyr, PSL            (+)           7.7         0.1                (-)
  4          11              53    M     6                               30                     (-)          300                        Pyr                 (+)           6.9         0.1                Thalassemia
  5          11              81    M     2                               4                      (-)          300                        EB, Pyr             (+)           6.8         0.2                (-)
  6          12              62    M     4                               30-45                  (-)          300                        Pyr, PSL            (-)           9           0.2                COPD
  7          12              72    M     6                               60                     NR           300                        RFP, ASP            (+)           11.7        NR                 Arrhythmia
  8          9               77    M     3                               14                     NR           NR                         EB, Pyr, SM         (+)           5           0.1                (-)
  9          13              47    M     1.5                             22                     (+)          300                        RFP, EB, PRZ        (+)           7.7         0                  (-)
  10         14              7     M     9                               45                     (-)          12mg/kg                    (-)                 (+)           3.6         0                  Liver dysfunction
  11         10              7     F     6                               15                     NR           15mg/kg                    Pyr                 (+)           6           NR                 (-)
  12         10              6     M     7                               14                     NR           15mg/kg                    Pyr                 (-)           6           NR                 (-)
  13         15              79    F     1.5                             10                     (-)          150                        RFP, EB, Pyr        (-)           6.3         1                  (-)
  14         2               47    F     1                               119                    NR           200                        PSL, TAC            (+), CyA      5.8         NR                 MG, SLE
  15         3               34    F     6                               NR                     NR           NR                         NR                  (+)           4           0.3                (-)
  16         This report     41    F     2.5                             14                     (-)          250                        PSL                 (+)           5.9         0.1                Sarcoidosis

PAS: para-amino salicylic acid, Pyr: Pyridoxine, EB: ethambutol, PB: Phenobarbitone, NR: not reported, PSL: prednisone, COPD: chronic obstructive pulmonary desease, RFP: rifampicin, ASP: aspirin, SM: streptomycin, PRZ: pyrazinamide, TAC: tacrolimus, CyA: cyclosporin A, MG: myasthenia gravis, SLE: systemic lupus erythematosus

Whether or not the exacerbation of sarcoidosis requiring corticosteroid therapy affected the pathogenesis of INH-induced PRCA in our case is unclear. Mizobuchi et al. suggested that a T-cell mediated immunologic response might be associated with the pathogenesis of secondary PRCA ([@B7]). Collagen diseases such as RA and SLE are thought to be associated with PRCA. However, the relationship between PRCA and sarcoidosis remains obscure. Additional studies of drug-induced PRCA in the presence of autoimmune disorders are required to elucidate the mechanism of INH-induced PRCA.

In 16 previous reports of INH-induced PRCA ([Table 2](#t002){ref-type="table"}), the sex ratio was 10:6 (male:female), and the average age of onset was 47.1 years, with a wide age distribution (from infants to elderly adults). Blood transfusion was required in \>80% of cases with INH-induced PRCA because the mean period of INH intake prior to the diagnosis was approximately 4.4 months ([Table 3](#t003){ref-type="table"}); therefore, anemia had progressed to an average hemoglobin level of \<7.0 g/dL in patients on long-term anti-tuberculosis therapy. However, transfusion may not be mandatory, but may rather depend on the health status of the patient. Most cases of INH-induced PRCA improved after the discontinuation of INH alone, except for one case with underlying MG and SLE ([@B2]). In three cases, INH was re-administered; PRCA recurred in all three ([@B8]-[@B10]). In the case of the patient with MG and SLE, cyclosporine A was added to the existing treatment of PSL; this patient had a longer period of recovery from PRCA (119 days) ([@B2]) than the other 15 patients.

###### 

Patient's Demographics.

  Variables              n=16             
  ---------------------- ---------------- -------------
  Age (year)             Median (range)   47 (6 - 79)
  Gender                 male / female    10 / 6
  Duration of exposure   (months)         4.4
  Recovery days          (Days)           29.1
  Cooms test             \+ / -           2 / 7
  Transfusion            Yes / No         13 / 3
  Lowest Hb              g/dL             6.4
  Lowest reticulocyte    \%               0.2

In recent years, the increased use of biological preparations has increased the need for anti-tuberculous treatment, including treatment of LTBI. Furthermore, with medical advances, various targeted molecular therapies have been developed, suggesting an even greater need for anti-tuberculosis treatment. Therefore, the use of INH monotherapy for the treatment of LTBI, as in the present case, is expected to increase. It is therefore important to make physicians aware of INH-induced PRCA.

In summary, INH-induced PRCA presents approximately 4.4 months after starting INH. The average hemoglobin level at the diagnosis is 6.4 g/dL, as discovery often happens late. Notably, PRCA recurred in all three cases in which INH was re-administered, suggesting that this practice should be avoided.

**The authors state that they have no Conflict of Interest (COI).**

We wish to thank Ms. Risa Kanai and Ms. Keiko Kogure for their assistance in preparing this manuscript.

[^1]: Correspondence to Dr.　Yasuyuki Saito, <sprq6fc9@road.ocn.ne.jp>
